Your browser doesn't support javascript.
loading
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors.
Wang, Zhenguang; Li, Na; Feng, Kaichao; Chen, Meixia; Zhang, Yan; Liu, Yang; Yang, Qingming; Nie, Jing; Tang, Na; Zhang, Xingying; Cheng, Chen; Shen, Lianjun; He, Jiaping; Ye, Xun; Cao, Wei; Wang, Haoyi; Han, Weidong.
Afiliación
  • Wang Z; Medical School of Chinese PLA, Beijing, China.
  • Li N; Department of Biotherapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Feng K; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • Chen M; Department of Biotherapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Zhang Y; Department of Biotherapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Liu Y; Department of Biotherapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Yang Q; Department of Biotherapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Nie J; Department of Biotherapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Tang N; Department of Biotherapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Zhang X; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • Cheng C; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • Shen L; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • He J; School of Life Sciences, University of Science and Technology of China, Hefei, China.
  • Ye X; Gracell Biotechnologies (Shanghai) Co., Ltd, Shanghai, China.
  • Cao W; Gracell Biotechnologies (Shanghai) Co., Ltd, Shanghai, China.
  • Wang H; Gracell Biotechnologies (Shanghai) Co., Ltd, Shanghai, China.
  • Han W; Gracell Biotechnologies (Shanghai) Co., Ltd, Shanghai, China. william.cao@gracellbio.com.
Cell Mol Immunol ; 18(9): 2188-2198, 2021 09.
Article en En | MEDLINE | ID: mdl-34381179
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cell Mol Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cell Mol Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: China